scholarly journals A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D

2017 ◽  
Vol 144 (1) ◽  
pp. 96-100 ◽  
Author(s):  
David M Hyman ◽  
Michael W Sill ◽  
Heather A Lankes ◽  
Richard Piekarz ◽  
Mark S Shahin ◽  
...  
Keyword(s):  
Gynecologic Oncology ◽  
Uterine Leiomyosarcoma ◽  
Gynecologic Oncology Group ◽  
Phase 2 ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Phase 2 Study

Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study

2002 ◽  
Vol 85 (3) ◽  
pp. 507-510 ◽  
Author(s):  
John H. Edmonson ◽  
John A. Blessing ◽  
Jonathan A. Cosin ◽  
David Scott Miller ◽  
David E. Cohn ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Uterine Leiomyosarcoma ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study

A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16512-e16512 ◽  
Author(s):  
David Michael Hyman ◽  
Michael Sill ◽  
Jonathan K Cho ◽  
Heather A. Lankes ◽  
Richard Piekarz ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Uterine Leiomyosarcoma ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study

scholarly journals A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study

2012 ◽  
Vol 124 (1) ◽  
pp. 48-52 ◽  
Author(s):  
Bradley J. Monk ◽  
John A. Blessing ◽  
Daron G. Street ◽  
Carolyn Y. Muller ◽  
James J. Burke ◽  
...  
Keyword(s):  
Phase Ii ◽  
Gynecologic Oncology ◽  
Uterine Leiomyosarcoma ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study
Sign in / Sign up

Export Citation Format

Share Document